Join Our Talent Network Here
Parallel Bio · Remote · location not stated
Pay not listedFull-time
Parallel BioViennaFull-timeOn-site
Pay listed in EUR · see posting
The employer took it down 3 days ago, after 17 days open. Here are similar open jobs.
Parallel Bio · Remote · location not stated
Pay not listedFull-time
Parallel Bio · San Francisco, CA
Full-timeOn-site
Parallel Bio · San Francisco, CA
Full-timeOn-site
Parallel Bio · San Francisco, CA
Full-timeOn-site
Parallel Bio · San Francisco, CA
Full-timeOn-site
Parallel Bio · San Francisco, CA
Full-timeOn-site
Summary, requirements and match are for US jobs for now.
From Parallel Bio’s careers site
THE MISSION
More than 95% of drugs that pass animal testing fail in human trials. A single new drug takes about $2.6 billion and 12.5 years to develop, and most of that effort goes to candidates that were never going to work in people.
AI was supposed to change this. But most AI for drug discovery is still trained on the same inputs that got us here: animal data, irreproducible papers, and cell lines that don’t respond like living tissue. A model can only learn the biology it’s shown, and no amount of scale or compute fixes bad data.
What’s missing is data on how living human tissue responds to a drug, across the range of people who will actually take it. That data barely exists, because there has been no way to generate it at scale without putting patients at risk.
Parallel Bio grows it. Our expert biologists build living human immune systems, called immune organoids, from a proprietary biobank spanning ages, sexes, ancestries and disease states. That means we can ask how a drug behaves in an older patient, a specific ancestry or an autoimmune background, not just in an average donor. We've already modeled immunotoxicology, immunogen stimulation and two autoimmune diseases, with more on the way. Our founders are world experts in scalable organoids. Robert is a Stanford-trained immunologist. Juliana trained in the lab that invented the first organoid and later automated them at System1 Biosciences.
We run these experiments in an AI-driven robotic lab, and every experiment makes our world model smarter, which in turn chooses better experiments. We build every layer ourselves: the biology, the robotics, the data infrastructure, and the model that orchestrates it all. The whole lab is callable over API and MCP, so AI agents can design and run real biological experiments, within safety limits we set. For biologists, that means asking questions at a scale and pace no bench can match. For engineers, it means building AI that learns from real human biology instead of the literature.
It's already working. Our platform is 87% concordant with clinical outcomes, compared with roughly 3% translational success for animal models. Five Fortune 500 companies use it to test drugs, and our data has informed a Phase 1 trial. We've raised ~$30M from AIX Ventures, Marc Benioff, Jeff Dean and Y Combinator. With the FDA Modernization Act 3.0 and the FDA's March 2026 validation framework, regulation is moving our way.
The opportunity is generational. We're building the first scaled engine for real human biological data, and using it to know which drugs will work in people before they ever reach a trial.
The Role
Note to candidates: the list below describes a strong profile, not a set of hard requirements. If you do not match every point but believe you are a strong candidate, please apply.
Our platform runs high-throughput immune organoid experiments to accelerate the development of new therapeutics. Building the next generation of models means building the culture formats they run in: the architecture of the construct, the hardware that holds it, and how separate compartments are brought into contact.
There is no established answer to any of that. The approach will be arrived at through successive prototypes rather than selected off the shelf, and setting the technical direction and the standard for what a finished format looks like is part of the role.
The work is done in close partnership with the assay development and platform teams across sites, so that what is built at the bench holds up when it becomes a process running at throughput. Breadth of immunological background matters more here than depth in any single indication, since the work will span disease areas as the platform develops.
The high-level goals for this role are fourfold:
1. Advance the architecture and performance of our organoid models, including new approaches to integrating immune cells into tissue constructs.
2. Design the physical formats that multi-organoid systems will need, including plate architecture, how organoids are nested, and whether and how they are allowed to interact.
3. Develop co-culture systems that combine immune organoids with other tissues to support disease modeling across multiple indications.
4. Bring bench-level automation into routine culture work, from custom culture hardware through to automated media handling.
This is a hands-on role with a high degree of independence at the bench. The project is one to own end to end: designing and building the solutions, making the technical calls that move the work forward, and running several workstreams in parallel. The role works closely with automation and software teams across sites.
Note that maintaining cell cultures and experimental continuity requires some weekend work on a rotating basis.
Areas of Responsibility
Organoid engineering
Multi-organoid and multi-tissue formats
Transfer and automation
Team and culture
Job Requirements
Technical abilities
Independence and problem-solving
Parallel Bio is an equal opportunity employer committed to fostering an inclusive and respectful workplace. We encourage applications from individuals of all backgrounds, regardless of age, gender, ethnicity, religion, disability, or sexual orientation.
Something wrong with this job? Report it · This flag looks wrong